Abstract
Background Little is known about the effect of the COVID-19 pandemic on mental health status during the lockdown period. Therefore, this study was conducted to assess prevalence of depression, anxiety and depression-anxiety comorbidity, and associated factors during the COVID-19 lockdown in Nepal.
Methods A quantitative cross-sectional study was conducted among the general population of Nepal. Data was collected from April 9 to April 16, 2020 using an e-questionnaire which was shared through different popular social media. A total of 349 participants were included. Self-reported depression and anxiety were assessed using the Patient Health Questionnaire and Generalized Anxiety tools respectively. Logistic regression analysis was conducted to identify the factors associated with depression, anxiety and depression and anxiety co-morbidity.
Results The prevalence rates of depression, anxiety and depression-anxiety co-morbidity were found to be 34.0%, 31.0% and 23.2% respectively. The multi-variate analysis showed that females, those living alone, health professionals and those who spent more time in accessing information about COVID-19 were significantly more likely to have depression, anxiety and depression-anxiety co-morbidity.
Conclusions High rates of depression and anxiety and co-morbidity were found to be prevailing among the general population during the COVID-19 pandemic lockdown in Nepal. The results suggest that only the scientific, but contextually appropriate messages about the disease should be disseminated to reduce unnecessary fears and anxiety. Awareness interventions to promote mental wellbeing need to be integrated into the response interventions. Community mental health care should be made accessible to at-risk groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has not received any funding from elsewhere.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data set for this study has been uploaded as the supplementary document.
